Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Cardiology

  • Home
  • Specialties
  • Cardiology
Cardiomyopathy Gene Therapy Reaches an Inflection Point: From AAV Delivery to Precision Genome Editing
Posted inCardiology Internal Medicine news

Cardiomyopathy Gene Therapy Reaches an Inflection Point: From AAV Delivery to Precision Genome Editing

Posted by MedXY By MedXY 05/12/2026
Gene therapy for cardiomyopathy is moving from concept to clinic, but durable benefit will depend on solving delivery, immunogenicity, cargo, and safety barriers in the failing human heart.
Read More
Tricuspid Valve Replacement Outcomes by Baseline Tricuspid Regurgitation Severity: TRISCEND II Trial
Posted inCardiology news

Tricuspid Valve Replacement Outcomes by Baseline Tricuspid Regurgitation Severity: TRISCEND II Trial

Posted by MedXY By MedXY 05/12/2026
TRISCEND II showed that transcatheter tricuspid valve replacement with EVOQUE markedly reduced tricuspid regurgitation and improved clinical outcomes across baseline severity levels, with a stronger signal for benefit in massive or torrential TR.
Read More
Why the cTnI/cTnT Ratio May Matter: A New Signal for Distinguishing Acute Necrotic From Chronic Myocardial Injury
Posted inCardiology news Pathology & Lab Medicine/Bệnh học

Why the cTnI/cTnT Ratio May Matter: A New Signal for Distinguishing Acute Necrotic From Chronic Myocardial Injury

Posted by MedXY By MedXY 05/12/2026
A large multicohort and experimental study suggests the cTnI/cTnT ratio is biologically informative, separates acute from chronic myocardial injury, and modestly improves type 1 versus type 2 MI discrimination.
Read More
Sacubitril/Valsartan Improved Exercise Pulmonary Hemodynamics and Dynamic Atrial Functional Mitral Regurgitation in HFpEF: Interpreting the PRAISE-MR Randomized Trial
Posted inCardiology Internal Medicine news

Sacubitril/Valsartan Improved Exercise Pulmonary Hemodynamics and Dynamic Atrial Functional Mitral Regurgitation in HFpEF: Interpreting the PRAISE-MR Randomized Trial

Posted by MedXY By MedXY 05/12/2026
In symptomatic HFpEF with atrial functional mitral regurgitation, sacubitril/valsartan improved exercise hemodynamics, peak VO2, symptoms, biomarkers, and stress-induced MR burden over 6 months versus standard care.
Read More
A GOLD Science Committee Perspective on Exacerbations and Cardiovascular Risk In COPD
Posted inCardiology news Respiratory

A GOLD Science Committee Perspective on Exacerbations and Cardiovascular Risk In COPD

Posted by MedXY By MedXY 05/11/2026
COPD exacerbations significantly increase cardiovascular risk for months. This article examines the link between COPD and heart disease, emphasizing proactive screening during flare-ups and evidence-based prevention strategies to improve survival rates.
Read More
Subclinical Hyperthyroidism Carries Measurable Risks of Atrial Fibrillation, Heart Failure, and Death in Primary Care
Posted inCardiology Diabetes & Endocrinology news

Subclinical Hyperthyroidism Carries Measurable Risks of Atrial Fibrillation, Heart Failure, and Death in Primary Care

Posted by MedXY By MedXY 05/10/2026
A large Dutch primary care cohort links subclinical hyperthyroidism to higher risks of atrial fibrillation, heart failure, and all-cause mortality, with particularly notable relative risks in younger adults and in patients with more strongly suppressed TSH.
Read More
Rationale and Design of CARDIO-TTRansform: A Phase 3 Trial of Eplontersen for Transthyretin Amyloid Cardiomyopathy
Posted inCardiology news

Rationale and Design of CARDIO-TTRansform: A Phase 3 Trial of Eplontersen for Transthyretin Amyloid Cardiomyopathy

Posted by MedXY By MedXY 05/10/2026
CARDIO-TTRansform is a global Phase 3 trial evaluating eplontersen's efficacy and safety in reducing cardiovascular events in transthyretin amyloid cardiomyopathy patients receiving standard care, including TTR stabilizers. With 1,432 participants, it aims to establish a new treatment paradigm.
Read More
Sex-Based Patterns and Trends in Transcatheter Aortic Valve Implantation
Posted inCardiology news

Sex-Based Patterns and Trends in Transcatheter Aortic Valve Implantation

Posted by MedXY By MedXY 05/10/2026
A 10-year Medicare study reveals women face higher immediate risks during TAVI procedures but demonstrate better long-term survival than men, despite declining representation in treatment.
Read More
Optimizing Antiplatelet Strategies in Complex PCI: Insights from the TAILORED-CHIP Trial and Evolving Evidence for Temporal Modulation
Posted inCardiology Clinical Updates news

Optimizing Antiplatelet Strategies in Complex PCI: Insights from the TAILORED-CHIP Trial and Evolving Evidence for Temporal Modulation

Posted by MedXY By MedXY 05/09/2026
This review synthesizes the TAILORED-CHIP trial results with recent evidence on antiplatelet modulation, highlighting the challenges of balancing ischemic and bleeding risks in high-risk PCI populations.
Read More
A New hs-cTnT Generation 6 Assay Matches Generation 5 for Myocardial Infarction Diagnosis While Labeling Fewer Patients as Myocardially Injured
Posted inCardiology Emergency Medicine news

A New hs-cTnT Generation 6 Assay Matches Generation 5 for Myocardial Infarction Diagnosis While Labeling Fewer Patients as Myocardially Injured

Posted by MedXY By MedXY 05/09/2026
In suspected myocardial infarction, hs-cTnT-gen6 showed diagnostic accuracy comparable to gen5, produced fewer myocardial injury classifications, and supported highly sensitive ESC 0/1-hour and 0/2-hour rule-out and rule-in pathways using assay-specific cutoffs.
Read More
Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study
Posted inCardiology news

Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study

Posted by MedXY By MedXY 05/09/2026
ORBITA-FIRE study reveals personalized physiological thresholds for angina that are lower than current diagnostic standards. These thresholds vary during exercise and predict PCI treatment success, challenging universal ischemia-based guidelines.
Read More
Optimizing the Referral Pathway for Mechanical Thrombectomy: Evidence-Based Perspectives on Mothership vs. Drip-and-Ship Models
Posted inCardiology Clinical Updates news

Optimizing the Referral Pathway for Mechanical Thrombectomy: Evidence-Based Perspectives on Mothership vs. Drip-and-Ship Models

Posted by MedXY By MedXY 05/09/2026
This review synthesizes recent evidence comparing 'mothership' and 'drip-and-ship' strategies in acute ischemic stroke, highlighting functional benefits of direct transport and the critical 43-minute delay threshold.
Read More
Targeting Skeletal Muscle Myosin ATPase May Reduce Resting Energy Waste in Heart Failure With Reduced Ejection Fraction
Posted inCardiology Internal Medicine news

Targeting Skeletal Muscle Myosin ATPase May Reduce Resting Energy Waste in Heart Failure With Reduced Ejection Fraction

Posted by MedXY By MedXY 05/06/2026
An ex vivo human skeletal muscle study suggests that myosin ATPase inhibition with mavacamten normalizes excessive resting ATP consumption in HFrEF myofibres, identifying a mechanistically novel strategy to address peripheral metabolic inefficiency and exercise intolerance.
Read More
AI-ECG Identified Left Ventricular Systolic Dysfunction in Kenya With High Sensitivity and Excellent Rule-Out Performance
Posted inAI Cardiology news

AI-ECG Identified Left Ventricular Systolic Dysfunction in Kenya With High Sensitivity and Excellent Rule-Out Performance

Posted by MedXY By MedXY 05/06/2026
In Kenyan outpatient clinics, an AI-enabled ECG algorithm showed strong discrimination for left ventricular systolic dysfunction, with 95.6% sensitivity and 99.1% negative predictive value against echocardiography.
Read More
Long-Term SAFE-PAD Data Reassure on Mortality After Paclitaxel-Coated Femoropopliteal Interventions
Posted inCardiology Internal Medicine news

Long-Term SAFE-PAD Data Reassure on Mortality After Paclitaxel-Coated Femoropopliteal Interventions

Posted by MedXY By MedXY 05/06/2026
In Medicare patients undergoing femoropopliteal revascularization, drug-coated devices were not associated with higher long-term mortality, supporting the safety of paclitaxel-coated technology after years of regulatory concern.
Read More
A New Pediatric VAD Driver Shows High Reliability and Preserves Mobility Without Major Device Malfunctions
Posted inCardiology news Pediatrics

A New Pediatric VAD Driver Shows High Reliability and Preserves Mobility Without Major Device Malfunctions

Posted by MedXY By MedXY 05/06/2026
In a prospective multicenter evaluation, the EXCOR Active Driver supported pediatric VAD care with no major device malfunctions and excellent short-term survival, while addressing a major unmet need in mobility and day-to-day function.
Read More
Epigenetic Regulation of Myocardial Inflammation: The Role of Macrophage PRMT9 and STAT1 Degradation in Acute Myocardial Infarction
Posted inCardiology Clinical Updates news

Epigenetic Regulation of Myocardial Inflammation: The Role of Macrophage PRMT9 and STAT1 Degradation in Acute Myocardial Infarction

Posted by MedXY By MedXY 05/05/2026
This review explores how PRMT9-mediated symmetric dimethylation of STAT1 serves as a critical check on proinflammatory macrophage activation, offering a novel therapeutic target for mitigating cardiac injury following myocardial infarction.
Read More
Earlier Mechanical Thrombectomy for Intermediate-Risk Pulmonary Embolism Improves Hemodynamics but Not In-Hospital Mortality
Posted inCardiology Critical Care news

Earlier Mechanical Thrombectomy for Intermediate-Risk Pulmonary Embolism Improves Hemodynamics but Not In-Hospital Mortality

Posted by MedXY By MedXY 05/05/2026
In a multicenter retrospective study, early mechanical thrombectomy within 12 hours of pulmonary embolism diagnosis improved pulmonary artery pressure reduction and reduced intubation, but did not significantly lower in-hospital mortality.
Read More
Pulmonary Arterial Hypertension Therapy Preserves Gas Exchange Overall in Portopulmonary Hypertension, but New Intrapulmonary Vascular Dilatations Can Emerge
Posted inCardiology news Respiratory

Pulmonary Arterial Hypertension Therapy Preserves Gas Exchange Overall in Portopulmonary Hypertension, but New Intrapulmonary Vascular Dilatations Can Emerge

Posted by MedXY By MedXY 05/04/2026
In PoPH, PAH-specific therapy did not worsen oxygenation overall, although responses varied widely. Hemodynamic changes influenced gas exchange, and some patients developed new intrapulmonary vascular dilatations during follow-up.
Read More
PCSK9 Inhibition Lowers LDL Cholesterol in Heterozygous Familial Hypercholesterolemia Regardless of LDL Receptor Variant Function
Posted inCardiology Internal Medicine news

PCSK9 Inhibition Lowers LDL Cholesterol in Heterozygous Familial Hypercholesterolemia Regardless of LDL Receptor Variant Function

Posted by MedXY By MedXY 05/03/2026
In a pooled nonrandomized phase 3 analysis, monthly lerodalcibep reduced LDL-C by about 50% in heterozygous familial hypercholesterolemia, with similar efficacy across LDLR functional variant categories and broad attainment of guideline-based LDL-C goals.
Read More

Posts pagination

1 2 3 … 50 Next page
  • More Enteral Protein Did Not Overcome Anabolic Resistance in Mechanically Ventilated Critical Illness
  • Persistent Challenges in Managing Monocular Deprivation Amblyopia: A Three-Decade Trend Analysis of Infant Unilateral Cataract Outcomes
  • Association of FOXC1 Duplications With Juvenile Open-Angle Glaucoma
  • Pigmentary Glaucoma Shows Higher Procedure Use and Worse Early Failure After LTP and MIGS Than Primary Open-Angle Glaucoma
  • Systematic V2 Vagal Stimulation Improves Detection of Post-Thyroidectomy Vocal Cord Dysfunction and May Better Guide Staged Surgery
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in